The following is a summary of the Tivic Health Systems, Inc. (TIVC) Q1 2024 Earnings Call Transcript:

Financial Performance:

• Tivic Health reported Q1 revenue of $334,000, a decrease of 11.2% from the same quarter last year primarily due to a significant decrease in unit sales resulting from a price increase of their product, ClearUp.

• Despite the drop in unit sales, the gross profit for the first quarter increased by 48% due to the ClearUP price increase and reduction in cost per unit.

• The company's total operating expenses for the first quarter dropped by 26% due to lower staff consulting, decreased professional fees, and reduced general/administrative expenses.

Business Progress:

• Tivic established a limited exclusive distribution agreement with McKesson for the distribution of ClearUP and initiated the restructuring of their supply chain to be better aligned with short-term business needs.

• Tivic successfully launched a new version of ClearUP that rectified a technical issue and completed a pilot clinical study for a novel form of noninvasive vagus nerve stimulation (VNS) with Feinstein Institutes for Medical Research.

• After the VNS program announcement, the company closed a $4 million financing round. The funds are expected to be used as working capital, which includes advancing the next phase of the VNS clinical program.

Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.